Glomerulonephritis (GN) is a broad term covering various conditions involving injury and inflammation of the glomerulus, which plays an important role in the filtration of blood in the kidney. As more glomeruli become damaged, a progressive decline in renal function can occur, leading to chronic kidney disease (CKD). There are various types of glomerulonephritis, including immunoglobulin A (IgA) nephropathy, focal segmental glomerulosclerosis (FSGS), lupus nephritis (LN), and membranous nephropathy (MN). In the United States, these conditions are typically managed by nephrologists. With few approved drug treatments available, prescribers are required to consider various off-label immunosuppressant agents that may be able to limit the damage and inflammation in the glomeruli. The recent approval of GSK’s Benlysta (belimumab) and Aurinia Pharmaceuticals’ Lupkynis (voclosporin) for LN may see a change in the treatment paradigm for this specific GN type, but also more broadly.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use, so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.